Spending on direct-to-consumer advertising (DTCA) of prescription drugs has increased dramatically in the past several years. An unresolved question is whether such advertising leads to inappropriate prescribing. In this study, the authors use survey and administrative data to determine the association of DTCA with the appropriate prescribing of cyclooxygenase-2 (COX-2) inhibitors for 1,382 patients. Treatment with either a COX-2 or a traditional nonsteroidal anti-inflammatory drug (NSAID) was defined as appropriate or not according to three different definitions of gastrointestinal risk. Patients who saw or heard a COX-2 advertisement and asked their physician about the advertised drug were significantly more likely to be prescribed a COX-2 (versus a NSAID, as recommended by evidence-based guidelines) than all other patients. Findings also suggest that some patients may benefit from DTCA. The authors discuss the need for balanced drug information for consumers, increased physician vigilance in prescribing appropriately, and further study of DTCA.
Aday, L. A.1996. Designing and conducting health surveys. 2nd ed.San Francisco: Jossey-Bass.
2.
Aikin, K. J.2002. Direct-to-consumer advertising of prescription drugs: Preliminary patient survey results. Bethesda, MD: Food and Drug Administration.
3.
Andersen, R. M., and P. L. Davidson. 2001. Improving access to care in America: Individual and contextual indicators. In Changing the U.S. health care system, edited by R. M. Andersen, T. H. Rice, and G. F. Kominski. San Francisco: Jossey-Bass, 3–30.
4.
Batchlor, E., and M. Laouri. 2003. Pharmaceutical promotion, advertising, and consumers. Health Affairs. http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.109v1.pdf.
5.
Bombardier, C., L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, M. Bosi Ferraz, C. J. Hawkey, M. C. Hochberg, T. K. Kvien, and T. J. Schnitzer. 2000. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine343 (21): 1520–1528.
6.
Bourque, L. B., and E. P. Fielder. 1995. How to conduct self-administered and mail surveys. Thousand Oaks, CA: Sage.
7.
Cheetham, T. C., G. Levy, and M. Spence. 2003. Predicting the risk of gastrointestinal bleeding due to nonsteroidal anti-inflammatory drugs: NSAID electronic assessment of risk. Journal of Rheumatology30 (10): 2241–2244.
8.
Clark, D. O., M. Von Korff, K. Saunders, W. M. Baluch, and G. E. Simon. 1995. A chronic disease score with empirically derived weights. Medical Care33 (8): 783–795.
9.
Eisenberg, J. M.1986. Doctors’ decisions and the cost of medical care: The reasons for doctors’ practice patterns and ways to change them. Ann Arbor, MI: Health Administration Press Perspectives.
10.
Emery, P., H. Zeidler, T. K. Kvien, M. Guslandi, R. Naudin, H. Stead, K. M. Verburg, P. C. Isakson, R. C. Hubbard, and G. S. Geis. 1999. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison. Lancet354:2106–2111.
11.
Fischer, M. A., and J. Avorn. 2004. Economic implications of evidence-based prescribing for hypertension. Can better care cost less?Journal of the American Medical Association291 (15): 1850–1856.
12.
Food and Drug Administration News. 2004. FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product. Available at http://%20www.fda.gov/bbs/topics/news/2004/NEW01122.html.
13.
Humphreys, A., and C. Boersig. 2004. Tenth annual report on DTC: Consumer advertising fills the gap. Med Ad News23 (6): 1-1, 40–53.
14.
Kaiser Permanente Medical Care Program. 2001. COX-2 guidelines: NSAID GI risk strategizer. In Drug formulary, edited by Monica A. Yoshingaga, Mirta Millares, and Susan Nakahiro. Madison, OH: Lexi-Comp.
15.
Kravitz, R. L., R. M. Epstein, M. D. Feldman, C. E. Franz, R. Azari, M. S. Wilkes, L. Hilton, and P. Franks. 2005. Influence of patients’ requests for direct–to–customer advertised antidepressants. Journal of the American Medical Association293(16): 1995-2002.
16.
Laine, L.2001. Approaches to nonsteroidal anti-inflammatory drug use in the high risk patient. Gastroenterology120 (3): 594–606.
17.
Levit, K., C. Cowan, H. Lazenby, A. Sensenig, P. McDonnell, J. Stiller, A. Martin, and the Health Accounts Team. 2000. Health spending in 1998: Signals of change. Health Affairs19 (1): 124–132.
18.
Merck Product News. 2004. Merck announces voluntary worldwide withdrawal of Vioxx. Available at http://www.merck.com/newsroom/press_releases/product/2004_0930.html.
19.
Mintzes, B., M. L. Barer, R. L. Kravitz, A. Kazanjian, K. Bassett, J. Lexchin, R. G. Evans, R. Pan, and S. A. Marion. 2002. Influence of direct-to-consumer pharmaceutical advertising and patients’ requests on prescribing decisions: Two-site cross-sectional survey. British Medical Journal324:278–79.
20.
Morrison, B. W., S. Christensen, W. Yuan, J. Brown, S. Amlani, and B. Seidenberg. 1999. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clinical Therapeutics21 (6): 943–953.
21.
National Institute for Health Care Management. 1999. Factors affecting the growth of prescription drug expenditures. Available at http://www.nihcm.org/FinalText3.pdf.
22.
National Institute for Health Care Management. 2001. Prescription drugs and mass media advertising, 2000. Available at http://www.nihcm.org/DTCbrief.pdf.
23.
Sandman, D., E. Simantov, and C. An. 2000. Out of touch: American men and the health care system: Commonwealth Fund Men’s and Women’s Health Survey Findings. Available at http://www.cmwf.org/programs/women/sandman_outoftouch_374.pdf.
24.
Silverstein, F. E., G. Faich, J. L. Goldstein, L. S. Simon, T. Pincus, A. Whelton, R. Makuch, G. Eisen, N. M. Agrawal, W. F. Stenson, A. M. Buss, W. W. Zhao, J. D. Kent, J. B. Lefkowith, K. M. Verburg, and G. S. Geis. 2000. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoporosis and rheuma toid arthritis: The CLASS study, a randomized controlled trial. Journal of the American Medical Association284 (10): 1247–1255.
25.
Singh, G., D. R. Ramsey, G. Triadafilopoulus, B. W. Brown, and R. R. Balise. 1998. GI score: A simple self-assessment instrument to quantify risk of serious NSAID-related GI complications in RA and OA. Arthritis and Rheumatism41 (9): S75-S75.
26.
Weissman, J. S., D. Blumenthal, A. J. Silk, K. Zapert, M. Newman, and R. Leitman. 2003. Consumers’ reports on the health effects of direct-to-consumer drug advertising.Health Affairs. http://content.healthaffairs.org/cgi/content/full/hlthaff.w3.82v1/DC1.
27.
Wilkes, M. S., R. A. Bell, and R. L. Kravitz. 2000. Direct-to-consumer prescription drug advertising: Trends, impact, and implications. Health Affairs19 (2): 110–128.
28.
Zachry, W. M., M. D. Sheperd, M. J. Hinich, J. P. Wilson, C. M. Brown, and K. A. Lawson. 2002. Relationship between direct-to-consumer advertising and physician diagnosing and prescribing. American Journal of Health-System Pharmacy59 (1): 42–49.
